Search

Displaying results 5871 - 5880 of 10000 in total
  1. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. … It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S.

    Products: TIGECLIN ® POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE., TIGEVITAE® 50 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE
  2. Drug

    Mivebresib

    go.drugbank.com/drugs/DB21300
    Investigational

    Mivebresib has a monoisotopic molecular weight of 459.11 Da. … Mivebresib is a small molecule drug.

  3. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory

    Synonyms: human cytomegalovirus (CMV) promoter and terminated with a 3' untranslated region and a simian virus 40 (SV40) polyadenylation signal, gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteins under control of a
  4. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    such as cancer and rheumatoid arthritis. … PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets.

  5. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. … CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of

  6. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). … ," as well as notification of health care providers.

  7. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  8. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    [L53203] It has been under investigation in humans since at least 2012. … Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.

  9. Drug

    Teduglutide

    go.drugbank.com/drugs/DB08900
    ApprovedInvestigational

    Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix is a synthetically derived thyroid hormone replacement preparation. … It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight.